Prescient Therapeutics (PTX) is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of solid and hematological cancers.

The Company’s novel compounds inhibit key tumor survival pathways, inhibiting cancer growth and overcoming resistance to prior therapies.

Latest Announcements


30/11/2016
Results of Annual General Meeting
02/11/2016
Receipt of R&D Tax Rebate
28/10/2016
Notice of Annual General Meeting/Proxy Form
28/10/2016
September 2016 Appendix 4C – Quarterly
26/09/2016
First Patient at Moffitt dosed in Phase 1b/2 breast trial
13/09/2016
Rodman & Renshaw Global Investment Conference Presentation